Related Experiment Video
Updated: Feb 11, 2026

Generation of Human Kidney Tubuloids from Tissue and Urine
Published on: April 16, 2021
Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA
Joanna Nizioł1, Vincent Bonifay2, Krzysztof Ossoliński3
1Faculty of Chemistry, Rzeszow University of Technology, 35-959, Rzeszow, Poland. jniziol@prz.edu.pl.
Abstract:
Renal cell carcinoma (RCC) is the most prevalent and lethal malignancy of the kidney. Despite all the efforts made, no tissue biomarker is currently used in the clinical management of patients with kidney cancer. A search for possible biomarkers in urine for clear cell renal cell carcinoma (ccRCC) has been conducted. Non-targeted metabolomic analyses were performed on paired samples of surgically removed renal cancer and normal tissue, as well as on urine samples. Extracts were analyzed by liquid chromatography/high-resolution mass spectrometry (LC-HRMS). Hydroxybutyrylcarnitine, decanoylcarnitine, propanoylcarnitine, carnitine, dodecanoylcarnitine, and norepinephrine sulfate were found in much higher concentrations in both cancer tissues (compared with the paired normal tissue) and in urine of cancer patients (compared with control urine). In contrast, riboflavin and acetylaspartylglutamate (NAAG) were present at significantly higher concentrations both in normal kidney tissue as well as in urine samples of healthy persons. This preliminary study resulted in the identification of several compounds that may be considered potential clear cell renal carcinoma biomarkers. Graphical abstract PLS-DA plot based on LC-MS data for normal and cancer human tissue samples. The aim of this work was the identification of up- and downregulated compounds that could potentially serve as renal cancer biomarkers.
Insights
Researchers identified potential biomarkers for clear cell renal cell carcinoma (ccRCC) by analyzing kidney tissue and urine. Elevated levels of specific carnitines and norepinephrine sulfate in cancer patients may aid in early detection of this kidney cancer.
Area of Science:
- Metabolomics
- Biomarker Discovery
- Urology
- Oncology
Background:
- Renal cell carcinoma (RCC) is a significant cause of cancer-related mortality.
- Current clinical management of kidney cancer lacks validated tissue biomarkers.
- The need for reliable biomarkers for early diagnosis and treatment monitoring of ccRCC is critical.
Purpose of the Study:
- To identify potential urinary and tissue biomarkers for clear cell renal cell carcinoma (ccRCC).
- To investigate metabolic differences between cancerous and normal kidney tissues and associated urine samples.
- To discover novel up- and downregulated compounds indicative of renal cancer.
Main Methods:
- Non-targeted metabolomic analysis of paired surgically removed renal cancer and normal tissue.
- Analysis of urine samples from ccRCC patients and healthy controls.
- Liquid chromatography/high-resolution mass spectrometry (LC-HRMS) for compound identification.
Main Results:
- Hydroxybutyrylcarnitine, decanoylcarnitine, propanoylcarnitine, carnitine, dodecanoylcarnitine, and norepinephrine sulfate were significantly elevated in ccRCC tissues and patient urine.
- Riboflavin and N-acetylaspartylglutamate (NAAG) were found at higher concentrations in normal kidney tissue and healthy urine.
- These identified compounds show potential as diagnostic biomarkers for ccRCC.
Conclusions:
- The study successfully identified several candidate biomarkers for ccRCC.
- Metabolomic profiling of tissue and urine offers a promising approach for kidney cancer biomarker discovery.
- Further validation is required to establish these compounds as reliable clinical biomarkers for renal cell carcinoma.
More Related Videos
Related Concept Videos
Filtration and Urine Formation
Urine Studies II: Urine Culture and Sensitivity Test
Urine Studies I: Urinalysis
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
The pKa of a...
High-Resolution Mass Spectrometry (HRMS)
Serum Studies: Renal Function Tests

